期刊
JOURNAL OF AUTOIMMUNITY
卷 128, 期 -, 页码 -出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jaut.2022.102814
关键词
Inflammatory bowel diseases; Colitis; Murine models; Autophagy; Peptide-based treatment
类别
资金
- French Center National de la Recherche Scientifique (CNRS)
- Region Grand-Est
- Laboratory of Excellence Medalis [ANR-10-LABX-0034]
- IdEx Unistra [ANR-10-IDEX-0002]
- SFRI (STRAT'US project) [ANR-20-SFRI-0012]
- University of Strasbourg Institute for Advanced Study (USIAS)
- TRANSAUTOPHAGY COST Action [CA15138]
- Club francophone de l'autophagie (CFATG)
- European Regional Development Fund of the European Union
- ImmuPharma-France
- Ministere de la Recherche et de la Technologie
- Inserm (Institut national de la sante et de la recherche medicale) [UMR1071]
- INRAE (Institut national de recherche en agriculture, alimentation et environnement)
- French government's Agence Nationale de la Recherche through the program Investissements d'Avenir [16-IDEX-0001 I-SITE CAP 20-25]
- Carver Trust Collaborative Pilot Grant through the Carver College of Medicine at the University of Iowa
- American Cancer Society [ACS-IRG-15-176-41, ACS-IRG-18-165-43]
- Carver College of Medicine, University of Iowa Research Start-Up funds
Inflammatory bowel disease (IBD) is a growing global health problem, and there is currently a lack of safe and targeted medicines for its treatment. This study investigated the potential use of a therapeutic peptide, P140, which corrects autophagy dysfunctions, in three mouse models of colitis. The results showed that P140 treatment attenuated the severity of colitis and corrected the expression of autophagy markers and pro-inflammatory mediators. These findings suggest that the autophagy modulator P140 holds promise for the treatment of IBD.
Inflammatory bowel disease (IBD) is a serious public health problem in Western society with a continuing increase in incidence worldwide. Safe, targeted medicines for IBD are not yet available. Autophagy, a vital process implicated in normal cell homeostasis, provides a potential point of entry for the treatment of IBDs, as several autophagy-related genes are associated with IBD risk. We conducted a series of experiments in three distinct mouse models of colitis to test the effectiveness of therapeutic P140, a phosphopeptide that corrects autophagy dysfunctions in other autoimmune and inflammatory diseases. Colitis was experimentally induced in mice by administering dextran sodium sulfate and 2,4,6 trinitrobenzene sulfonic acid. Transgenic mice lacking both il-10 and iRhom2 -involved in tumor necrosis factor alpha secretion -were also used. In the three models investigated, P140 treatment attenuated the clinical and histological severity of colitis. Post-treatment, altered expression of several macroautophagy and chaperone-mediated autophagy markers, and of pro-inflammatory mediators was corrected. Our results demonstrate that therapeutic intervention with an autophagy modulator improves colitis in animal models. These findings highlight the potential of therapeutic peptide P140 for use in the treatment of IBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据